Regimen confers ‘meaningful’ benefit in aggressive lymphoma, may become a new standard

medpagetoday.com·May 30, 2026 · 8 h fa

Frontline Targeted Therapies Plus R-CHOP Boosts PFS in High-Risk B-Cell Lymphomas

morningstar.com·May 30, 2026 · 6 h fa

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL

fiercepharma.com·May 30, 2026 · 6 h fa

ASCO: With bispecifics on its heels, Incyte positions Monjuvi combo for first-line DLBCL

morningstar.com·May 29, 2026 · 1 g fa

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

medpagetoday.com·May 29, 2026 · 1 g fa

Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma

morningstar.com·May 29, 2026 · 1 g fa

Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma

endpoints.news·May 29, 2026 · 1 g fa

Bristol Myers details Phase 3 trial win for Pomalyst successor

liberoquotidiano.it·May 27, 2026 · 3 g fa

Mieloma multiplo: ecco la nuova indicazione di daratumumab | Libero Quotidiano.it

morningstar.com·May 29, 2026 · 1 g fa

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

morningstar.com·May 29, 2026 · 1 g fa

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia